agent-builder-types-aws-transform

v1.0.0 safe
3.0
Low Risk

Type stubs for boto3 TransformAgenticService client

🤖 AI Analysis

Final verdict: SAFE

The package shows no signs of malicious activity, with very low risks across all categories except metadata. The maintainer's single package suggests they might be new or less active, but there is insufficient evidence to conclude any malicious intent.

  • No network, shell, or obfuscation risks detected.
  • Low credential risk.
Per-check LLM notes
  • Network: No network calls detected, which is normal for a package focused on local transformations.
  • Shell: No shell execution detected, aligning with the expected behavior of a transformation tool.
  • Obfuscation: No obfuscation patterns detected, indicating low risk.
  • Credentials: No credential harvesting patterns detected, indicating low risk.
  • Metadata: The maintainer has only one package, which could indicate a new or less active account, raising some suspicion but not conclusive evidence of malice.

🔬 Heuristic Checks

✓ Outbound Network Calls

No suspicious network call patterns found

✓ Code Obfuscation

No obfuscation patterns detected

✓ Shell / Subprocess Execution

No shell execution patterns detected

✓ Credential Harvesting

No credential harvesting patterns detected

✓ Typosquatting

No typosquatting candidates detected

✓ Registered Email Domain

No author email provided

✓ Suspicious Page Links

All external links appear legitimate

✓ Git Repository History

No GitHub repository linked

  • No GitHub repository link found
⚠ Maintainer History score 2.0

1 maintainer concern(s) found

  • Author "AWS Transform Team" appears to have only 1 package on PyPI (new or inactive account)
✓ Known CVE Vulnerabilities

No known vulnerabilities found in OSV database.

💡 AI App Starter Prompt

Use this prompt to build a project with agent-builder-types-aws-transform
Build a simple Python application using the agent-builder-types-aws-transform package to demonstrate its core features.

💬 Discussion Feed

Leave a comment

No discussion yet. Be the first to share your thoughts!